Hyperimmune immunoglobulin for people with COVID-19

Catherine Kimber; Sarah J. Valk; Khai Li Chai; Vanessa Piechotta; Claire Iannizzi; Ina Monsef; Erica M. Wood; Abigail A. Lamikanra; David J. Roberts; Zoe McQuilten; Cynthia So-Osman; Lise J. Estcourt; Nicole Skoetz

doi:10.1002/14651858.cd015167

Hyperimmune immunoglobulin for people with COVID-19

Catherine Kimber, Sarah J. Valk, Khai Li Chai, Vanessa Piechotta, Claire Iannizzi, Ina Monsef, Erica M. Wood, Abigail A. Lamikanra, David J. Roberts, Zoe McQuilten, Cynthia So-Osman, Lise J. Estcourt, Nicole Skoetz^*

^*Corresponding author for this work

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. Using a living systematic review approach, to assess whether hyperimmune immunoglobulin therapy is effective and safe in the treatment of people with COVID-19; and to maintain the currency of the evidence.

Original language	English
Article number	CD015167
Number of pages	26
Journal	Cochrane Database of Systematic Reviews
Volume	2021
Issue number	10
DOIs	https://doi.org/10.1002/14651858.cd015167
Publication status	Published - 12 Oct 2021

Bibliographical note

Funding Information:
This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 101015756. The contents of this document reflect only the authors' view and the Commission is not responsible for any use that may be made of the information it contains.

Funding Information:
The research was supported by NHS Blood and Transplant and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.

Publisher Copyright:
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Access to Document

10.1002/14651858.cd015167

https://ora.ox.ac.uk/objects/uuid:bff4c6ec-1ef0-432b-ac59-74c25fcfda56/files/sv692t725g

Cite this

@article{df4e4b423ffa4fa083769b49921b37ea,

title = "Hyperimmune immunoglobulin for people with COVID-19",

abstract = "Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. Using a living systematic review approach, to assess whether hyperimmune immunoglobulin therapy is effective and safe in the treatment of people with COVID-19; and to maintain the currency of the evidence.",

author = "Catherine Kimber and Valk, {Sarah J.} and Chai, {Khai Li} and Vanessa Piechotta and Claire Iannizzi and Ina Monsef and Wood, {Erica M.} and Lamikanra, {Abigail A.} and Roberts, {David J.} and Zoe McQuilten and Cynthia So-Osman and Estcourt, {Lise J.} and Nicole Skoetz",

note = "Funding Information: This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 101015756. The contents of this document reflect only the authors' view and the Commission is not responsible for any use that may be made of the information it contains. Funding Information: The research was supported by NHS Blood and Transplant and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Publisher Copyright: Copyright {\textcopyright} 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.",

year = "2021",

month = oct,

day = "12",

doi = "10.1002/14651858.cd015167",

language = "English",

volume = "2021",

journal = "Cochrane Database of Systematic Reviews",

issn = "1361-6137",

publisher = "John Wiley & Sons Ltd.",

number = "10",

}

TY - JOUR

T1 - Hyperimmune immunoglobulin for people with COVID-19

AU - Kimber, Catherine

AU - Valk, Sarah J.

AU - Chai, Khai Li

AU - Piechotta, Vanessa

AU - Iannizzi, Claire

AU - Monsef, Ina

AU - Wood, Erica M.

AU - Lamikanra, Abigail A.

AU - Roberts, David J.

AU - McQuilten, Zoe

AU - So-Osman, Cynthia

AU - Estcourt, Lise J.

AU - Skoetz, Nicole

N1 - Funding Information: This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 101015756. The contents of this document reflect only the authors' view and the Commission is not responsible for any use that may be made of the information it contains. Funding Information: The research was supported by NHS Blood and Transplant and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Publisher Copyright: Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

PY - 2021/10/12

Y1 - 2021/10/12

N2 - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. Using a living systematic review approach, to assess whether hyperimmune immunoglobulin therapy is effective and safe in the treatment of people with COVID-19; and to maintain the currency of the evidence.

AB - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. Using a living systematic review approach, to assess whether hyperimmune immunoglobulin therapy is effective and safe in the treatment of people with COVID-19; and to maintain the currency of the evidence.

UR - http://www.scopus.com/inward/record.url?scp=85117068546&partnerID=8YFLogxK

U2 - 10.1002/14651858.cd015167

DO - 10.1002/14651858.cd015167

M3 - Article

AN - SCOPUS:85117068546

SN - 1361-6137

VL - 2021

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 10

M1 - CD015167

ER -

Hyperimmune immunoglobulin for people with COVID-19

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this